Literature DB >> 10462196

Facilitation of memory performance by a novel muscarinic agonist in young and old rats.

A C Ruske1, K G White.   

Abstract

AF150(S), a partial M1 muscarinic receptor agonist, was tested for its ability to improve performance in rats in a delayed matching-to-position task. Young and old rats received intraperitoneal injections of 0, 1, and 4 mg/kg of AF150(S). AF150(S) significantly enhanced matching accuracy for both young and old rats. Fits of exponential functions to discriminability measures showed that the enhancement was manifest as a reduction in the rate of forgetting. These results indicate that AF150(S) may be a useful therapeutic agent for improving cognitive function.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10462196     DOI： 10.1016/s0091-3057(99)00037-4

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN： 0091-3057            Impact factor:   3.533


  5 in total

Review 1.  Alzheimer's disease and age-related memory decline (preclinical).

Authors:  Alvin V Terry; Patrick M Callahan; Brandon Hall; Scott J Webster
Journal:  Pharmacol Biochem Behav       Date:  2011-02-24       Impact factor: 3.533

2.  Donepezil-induced improvement in delayed matching accuracy by young and old rhesus monkeys.

Authors:  Jerry J Buccafusco; Alvin V Terry
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

3.  Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M1 receptor agonist, in healthy younger adult and elderly subjects: a multiple ascending dose study.

Authors:  Charlotte Bakker; Tim Tasker; Jan Liptrot; Ellen P Hart; Erica S Klaassen; Robert Jan Doll; Giles A Brown; Alastair Brown; Miles Congreve; Malcolm Weir; Fiona H Marshall; David M Cross; Geert Jan Groeneveld; Pradeep J Nathan
Journal:  Alzheimers Res Ther       Date:  2021-04-21       Impact factor: 6.982

4.  A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M1 receptor agonist HTL0018318 in patients with mild-to-moderate Alzheimer's disease.

Authors:  Pradeep J Nathan; S Babli Millais; Alex Godwood; Odile Dewit; David M Cross; Janet Liptrot; Bharat Ruparelia; Stephen Paul Jones; Geor Bakker; Paul T Maruff; Gregory A Light; Alastair J H Brown; Malcolm Peter Weir; Miles Congreve; Tim Tasker
Journal:  Alzheimers Dement (N Y)       Date:  2022-02-23

Review 5.  Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies.

Authors:  Dapinder Kaur; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Simona Bungau
Journal:  Neurochem Res       Date:  2021-08-06       Impact factor: 3.996
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.